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Anti-TNF drugs are effective against psoriasis, although 20-30% of patients are non-
responders. Few pharmacogenomic studies have been performed to predict the response 
to anti-TNF drugs in psoriasis. We studied 173 polymorphisms to establish an 
association with the response to anti-TNF drugs in patients with moderate-to-severe 
plaque psoriasis (N=144). We evaluated the response using PASI75 at 3, 6, and 12 
months. The results of the multivariate analysis showed an association between 
polymorphisms in PGLYR4, ZNF816A, CTNNA2, IL12B, MAP3K1, and HLA-C genes 
and the response at 3 months. Besides, the results for polymorphisms in IL12B and 
MAP3K1 were replicated at 6 months. We also obtained significant results for IL12B 
polymorphism at 1 year. Moreover, polymorphisms in FCGR2A, HTR2A, and CDKAL1 
were significant at 6 months. This is the first study to show an association with these 
polymorphisms. However, these biomarkers should be validated in large-scale studies 












Psoriasis is a complex skin disease. Its etiology is unknown, but genetics and the 
immune system play a key role in its development 1. Tumor necrosis factor (TNF), 
interleukin (IL)-12, IL-23, and the HLA-C*0602 allele are the main genetic risk factors 
for psoriasis 2. Genome-wide association studies (GWAS) and candidate gene studies 
have provided initial data on these risk factors. TNFα and the p40 subunit of IL-12 and 
IL-23 are the current therapeutic targets in moderate-to-severe psoriasis (anti-TNF drugs 
and ustekinumab, respectively) 3. Therefore, genetic studies can reveal new therapeutic 
targets and increase our knowledge of the etiology and pathogenesis of psoriasis. 
Moderate-to-severe psoriasis can be treated using several anti-TNF drugs, including 
etanercept, adalimumab, and infliximab. Adalimumab and infliximab are antibodies, 
and etanercept is a dimeric fusion protein that acts against the proinflammatory 
cytokine, TNFα, which is involved in the development of psoriasis 3. Anti-TNF drugs 
are usually safe and well tolerated, but patients can develop adverse effects or not 
respond to treatment 3. Genetics can explain interindividual differences in the response 
to therapy. Few pharmacogenomic studies have been performed in psoriasis, and the 
results of the few studies performed have not been replicated 4-12. Therefore, we 
performed a candidate gene study to investigate single-nucleotide polymorphisms 
(SNPs) that can predict the response to anti-TNF drugs in Caucasian patients with 
moderate-to-severe plaque psoriasis. 
 




Our study included 144 patients recruited between 16/10/2007 and 17/12/2012 from 
four hospitals in Madrid, Spain (Hospital Universitario de la Princesa, Hospital 
Universitario Gregorio Marañón, Hospital Universitario Fundación Alcorcón, and 
Hospital Universitario Infanta Leonor). All patients were Caucasians aged ≥ 18 years 
with moderate-to-severe plaque psoriasis (defined according to the European consensus 
published by Mrowietz et al. [2011] 13) requiring treatment with biological drugs. The 
patients were treated with anti-TNF agents according to the Summary of Product 
Characteristics. Only patients who were naïve for anti-TNF treatment were included in 
the analysis. The parameter used to evaluate the effectiveness of treatment was the 
Psoriasis Area and Severity Index (PASI). Patients who achieved a 75% improvement 
over their baseline PASI (PASI75) were considered responders to treatment. We 
collected PASI75 data at 3, 6, and 12 months. All patients signed a written informed 
consent document to participate in this study. The protocol and informed consent 
document complied with Spanish legislation on biomedical research and were approved 
by the Ethics Committee for Clinical Investigation of Hospital Universitario de la 
Princesa. 
 
Sample processing and genotyping 
DNA was extracted from peripheral blood samples (EDTA 3 mL) using the MagNa 
Pure® System (Roche Applied Science, USA) and quantified in a NanoDrop® ND-
1000 Spectrophotometer (Wilmington, USA). Samples were stored at –80ºC in the 
Clinical Pharmacology Service. 
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A total of 173 polymorphisms were evaluated using the IlluminaVeracode genotyping 
platform (Human Genotyping Unit-CeGen, Madrid, Spain). A description of the SNPs 




Allele and genotype frequencies, Hardy-Weinberg equilibrium, and linkage 
disequilibrium were analyzed using SNPStats 15. The univariate analysis to evaluate the 
SNPs and the treatment response was performed using R 3.0.2. (SNPassoc package) 16 
and SNPStats. We tested different logistic regression models (codominant, dominant, 
recessive, and additive). The optimal model was selected using the lower Akaike 
Information Criterion (AIC). SNPs with p≤0.05 in the univariate analysis were included 
in the multivariate analysis. Moreover, when several SNPs were in linkage 
disequilibrium and were significant in the univariate analysis, we analyzed the 
association between haplotype and response using SNPstats. Statistical significance was 
set at p≤0.05. The results were expressed as the odds ratio (OR), 95% confidence 
interval (CI), and p-value. Efficacy data were also analyzed using ITT-LOCF 
(Intention-To-Treat Last Observation Carried Forward) method 17. 
The clinical variables compared between responders and non-responders included age at 
onset of psoriasis, type of psoriasis (I or II), weight, gender, presence or absence of 






The study population included 144 patients (84 men and 60 women) with moderate-to-
severe plaque psoriasis treated with anti-TNF drugs. The phenotypic characteristics of 
the patients are shown in Table 1. The mean age at onset of psoriasis was 28.51 ± 14.04 
years and the mean age when the first anti-TNF agent was prescribed was 43.61 ± 15.02 
years. 
The first anti-TNF drug was etanercept in 74 patients (51.39%), adalimumab in 42 
(29.17%), and infliximab in 28 (19.44%). Throughout treatment, almost all patients 
(97%) were treated as monotherapy. A total of 106 patients achieved a PASI75 response 
at 3 months of treatment (73.61%). Data for the evaluation of the clinical response are 
missing in some patients owing to loss of follow-up, side effects, remission, intermittent 
therapy, and/or patient's wish (Table 1). Before 6 months, 6 patients decided not to 
continue with the treatment and we missed PASI evaluation at 6 months owing to lack 
of follow-up. In addition, 3 patients stopped anti-TNF treatment at 3-4 months because 
of lack of efficacy and 2 patients because of side effects. Before 1 year, other 8 patients 
did not wish to continue with the therapy. Moreover, the treatment was withdrawn 
because of lack of efficacy (N=8, 7-9 months), side effects (N=3, 6-8 months) or 
remission (N=1, 8 months). Therefore, 11 and 31 patients did not reach the visits at 6 
and 12 months, respectively, and we included 133 and 113 patients to evaluate 
effectiveness at 6 months and 1 year of treatment. Of the 133 patients evaluated at 6 
months, 102 achieved PASI75 (76.69%); of the 113 patients evaluated at 1 year, 92 
achieved PASI75 (81.42%).  
We did not obtain significant results for the following clinical variables evaluated for 
response to the treatment: age at onset of psoriasis (p=0.620), type I or II psoriasis 
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(p=0.740), weight (p=0.830), gender (p=0.950), presence or absence of psoriatic 
arthritis (p=0.920), age at prescription of the first anti-TNF drug (p=0.380), presence of 
comorbidities (p=0.530 for dyslipemia, p=0.300 for hypertension, p=0.510 for diabetes, 
p=0.190 for obesity), and prior therapies (p=0.390 for methotrexate, p=0.200 for 
cyclosporine, p=0.980 for acitretin, p=0.055 for phototherapy, p=0.200 for efalizumab). 
 
Effectiveness  
All significant results in the univariate analysis at 3 months (PASI75) are shown in 
Table S1 (22 significant SNPs). Only 6 SNPs were significant in the multivariate 
analysis (Table 2). Of these, 4 were associated with a lack of achievement of PASI75: 
AG/GG in rs2916205 (PGLYRP4-24; OR=3.62), CC in rs9304742 (ZNF816A; 
OR=7.66), AA in rs11126740 (CTNNA2; OR=20.56), and AG/GG in rs2546890 
(IL12B; OR=3.22). However, patients with the CT/CC allele in rs96844 (MAP3K1; 
OR=0.17) and the CT/TT allele in rs12191877 (HLA-C; OR=0.30) responded better to 
anti-TNF drugs (Table 2).  
All significant results in the univariate analysis at 6 months (PASI75) are shown in 
Table S2 (17 significant SNPs). Only 5 SNPs were significant in the multivariate 
analysis (Table 3): carriers of the CT/CC genotype for rs1801274 (FCGR2A; 
OR=13.32), CT/TT for rs6311 (HTR2A; OR=5.60), and AG/GG for rs2546890 (IL12B; 
OR=4.14) were poor responders. Nevertheless, carriers of the CT/CC genotype of 
rs96844 (MAP3K1; OR=0.24) and carriers of CT/TT in rs6908425 (CDKAL1; 
OR=0.14) achieved a better therapeutic response (Table 3).  
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We also performed a multivariate logistic regression analysis for PASI75 at 1 year of 
treatment (N=113; Table 4 and Table S3). We only obtained significant results for 
rs2546890 in IL12B: patients with the AG/GG genotype were more likely to be non-
responders (Table 4). Moreover, rs2546890 is in linkage disequilibrium with rs6887695 
in IL12B (which was also significant in the univariate analysis for PASI75 at 1 year of 
treatment, p=0.014; Table S3). The haplotype results showed an association between the 
GC haplotype (rs2546890 and rs6887695, respectively) and non-response to anti-TNF 
drugs at 1 year of treatment (Table S4). 
The haplotype analysis (Table S4) showed an association between non-responders 
(PASI75) and the GACCT haplotype (rs2916205, rs821421, rs3006448, rs3006452, and 
rs3006457, respectively) in PGLYRP gene (p=0.028), TT haplotype (rs12191877 and 
rs10484554, respectively) in HLA-C (p=0.018), and TA haplotype (rs2073048 and 
rs2022544, respectively) in C6orf10 (p=0.032) at 3 months of treatment. None of these 
haplotypes were significant at 6 months or 1 year of treatment. However, analysis of 2 
SNPs in FOXP3 (rs2280883 and rs3761548) revealed significant results in men at 6 
months (TC haplotype; p=0.025; Table S4). 
The results with ITT-LOCF method showed 6 significant SNPs in rs1801274 
(FCGR2A; OR=6.53), rs6311 (HTR2A; OR=11.36), rs2546890 (IL12B; OR=3.27), 
rs6908425 (CDKAL1; OR=0.12), rs6028945 (MAFB; OR=0.12), and rs10945919 (QK1; 
OR=5.13) at 6 months of treatment (supplementary Table S5). Furthermore, we 
obtained 2 significant SNPs in rs96844 (MAP3K1; OR=0.20) and rs191190 




DISCUSSION AND CONCLUSIONS 
Polymorphisms in PGLYRP4-24 (rs2916205), ZNF816 (rs9304742), and CTNNA2 
(rs11126740) have been associated with psoriasis 18-21. However, the association 
between these SNPs and response to treatment has not yet been studied. Therefore, our 
study is the first to show an association between several SNPs and response to anti-TNF 
drugs in patients with moderate-to-severe plaque psoriasis. 
PGLYRP4 encodes a protein involved in immune responses which binds to 
peptidoglycan and bacterial lipopolysaccharide 22. This protein is found at the PSORS4 
locus, which is within the epidermal differentiation complex and is expressed in 
epithelial cells in the skin 18, 22, 23. Several polymorphisms in PGLYRP4 seem to increase 
the risk of developing Crohn’s disease 22, which is associated with psoriasis 2. In 
addition, Sun et al. (2006) did not find an association between this gene and moderate-
to-severe psoriasis in single SNP-based or haplotype-based tests in a case-control study 
18. We confirmed these results in a recent publication 14. However, when we studied 
SNPs in the PGLYRP4 gene, we found that carriers of the G allele of rs2916205 were 
3.62 times more likely not to respond to anti-TNF drugs (Table 2). Moreover, we found 
a significant GACCT haplotype in the PGLYRP gene (rs2916205, rs821421, rs3006448, 
rs3006452, and rs3006457, respectively) that was associated with no response to anti-
TNF drugs at 3 months (PASI75). 
In addition, we describe for the first time that C allele of rs9304742 in ZNF816A gene 
were 7.66 times more likely not to respond to treatment (Table 2). This gene encodes a 
zinc-finger protein that could play a role in the recognition of specific proteins and have 
several regulatory functions 19. Likewise, the SNP rs11126740 is found in CTNNA2 and 
considerably affected the response to treatment (PASI75) at 3 months in the study 
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population. A allele carriers were 20.56 times more likely not to respond to treatment 
(Table 2). This gene encodes a catenin alpha 2 (cadherin-associated protein) involved in 
cellular adhesion. Overexpression of basal layer cadherins results in abnormal 
keratinocyte differentiation, a typical feature of psoriasis 24. El Wahed Gaber et al. 
(2015) performed a study of gene expression of β-catenin (protein that interacts with α-
catenin during cell adhesion) and demonstrated deregulation of β-catenin in psoriatic 
skin 24. Therefore, these proteins may play a key role in the maintenance of normal 
tissue architecture.  
Furthermore, the frequency of T allele carriers for rs12191877 was 70.8% for 
responders and 52.6% for non-responders at 3 month of treatment (p=0.027; Table 2). 
This SNP has also been associated with psoriasis and is in linkage disequilibrium with 
HLA-C*0602 25, 26. HLA-C plays a role in the immune system by presenting peptides 
derived from the lumen of the endoplasmic reticulum. HLA-C*0602 and late-cornified 
envelope (LCE; I carriers) genotypes have been associated with better response to anti-
TNF drugs at 24 weeks (PASI75; N=116) 7. In this sense, we found that carriers of the T 
allele for rs12191877 (HLA-C) were 3.33 times more likely to respond to anti-TNFs 
(Table 2). We also found a significant TT haplotype for rs12191877 and rs10484554, 
respectively, in HLA-C that was associated with response to anti-TNF agents at 3 
months (PASI75). In contrast, the HLA-C*0602 allele has been associated with poor 
response to anti-TNF drugs 6. Moreover, the HLA-C*0602 allele has been associated 
with an increased and faster response to ustekinumab 27. Therefore, the HLA-C gene 
may play a relevant role in the development of the disease, as well as in the response to 
biological drugs. Ryan et al. (2014) compared the frequencies of HLA-C genotypes 
between responders and non-responders and found no significant results 5.  
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The results obtained for rs2546890 (IL12B) and rs96844 (MAP3K1) were replicated in 
our study at 3 and 6 months of anti-TNF treatment. Moreover, we replicated the 
association for rs2546890 at 1 year. Thus these SNPs could be predictors of anti-TNF 
response in the short and long terms. IL12 is a proinflammatory cytokine involved in 
the lymphocyte T helper 1 (Th1) pathway. This cytokine has been widely associated 
with psoriasis 28-30. Moreover, rs2546890 in IL12 has been associated with psoriasis 26. 
We previously evaluated the influence of polymorphisms in IL12B (rs6887695 and 
rs3212227) on the response to anti-TNF drugs 6 but found no association. However, our 
results did indicate that carriers of the G allele of rs2546890 (IL12B) were 3.22, 4.11, 
and 2.79 times more likely not to respond to treatment at 3 months, 6 months, and 1 
year, respectively, than patients carrying the AA genotype (Tables 2, 3, and 4). In 
addition, we found an association between the GC haplotype (rs2546890 and 
rs6887695, respectively) and response at 1 year of treatment (Table S4). Furthermore, 
we selected a series of SNPs in our previous study (see Table 2 by Prieto-Pérez et al. 
[2013]) 2. Among the SNPs 2, we found an association between carriers of the C allele 
of rs96844 (MAP3K1) and better response to anti-TNF drugs at 3 and 6 months of 
treatment (5.88-fold and 4.17-fold, respectively; Table 2 and 3). Bowes et al. (2009) 
also found an association between the minor allele (G) of rs96844 (MAP3K1) and a 
good response to anti-TNF drugs in patients with RA (N=428) 31. However, the authors 
did not validate their results in an independent cohort 31. 
In addition, we obtained significant results for rs1801274 in FCGR2A at 6 months of 
treatment. Prieto-Pérez et al. (2013) 2 showed this protein to be associated with the 
response to anti-TNF therapy in RA 32, 33 (see Table 2 of Prieto-Pérez et al. [2013]). 
FCGR2A encodes Fc-γ receptor on the cell surface of macrophages and neutrophils. In 
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our study, carriers of the C allele of rs1801274 were 13.32 times more likely to be non-
responders to anti-TNF drugs. Our results were consistent with those of Ramírez et al. 
(2012), who showed an association between the T allele (rs1801274) and a better 
response to anti-TNF drugs in patients with psoriatic arthritis 34, which is also 
associated with psoriasis 2. In contrast, Dávila-Fajardo et al. (2015) found an association 
between the C allele and a better response to adalimumab in patients with RA at 14 
weeks 35. Julià et al. (2013) analyzed rs1801274 (FCGR2A) but obtained no significant 
results for PASI75 at 12 weeks of treatment with anti-TNF drugs in psoriatic patients 12. 
Other SNPs associated with the response to anti-TNF drugs at 6 months of treatment in 
our population were rs6311 (HTR2A) and rs6908425 (CDKAL1). rs6311 in HTR2A 
(which encodes a serotonin receptor) was associated with late-onset psoriasis in a Thai 
population 36. Psoriasis is characterized by high production of cytokines that could be 
inhibited in the presence of 2,5-dimethoxy-4-iodoamphetamine (selective serotonin 
receptor agonist) 37. This inhibition was more pronounced in carriers of the T and C 
alleles of rs6314 and rs1328674, respectively, in patients with RA 37. Moreover, we 
found an association between psoriatic carriers of the T allele of rs6311 (HTR2A) and a 
worse response to anti-TNF drugs (5.60-fold). In addition, a gene-gene interaction was 
described for HTR2A and the major genetic risk factor for RA, HLA-DRB1 38. These 
results suggest that HTR2A may be associated with the immune system and could be a 
risk factor for psoriasis. Besides, rs6908425 (CDKAL1) has been described as a risk 
factor for psoriasis 39. Our results showed an association between carriers of the T allele 
of rs6908425 (CDKAL1), which has an unknown function, and better response to anti-
TNF drugs (7.14-fold) at 6 months. Nevertheless, the influence of this SNP on the 
response of anti-TNFs has not been studied yet. 
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Other haplotypes associated with response to anti-TNF drugs were TA for rs2073048 
and rs2022544, respectively, in C6orf10 (PASI75 at 3 months) and TC for rs2280883 
and rs3761548, respectively, in FOXP3 (PASI75 at 6 months in men). SNPs in C6orf10 
and FOXP3 genes were previously associated with psoriasis, but not with response to 
anti-TNF drugs 25, 40-42. FOXP3 is expressed by regulatory T cells and has been 
associated with some autoimmune disorders 41. While the function of the protein 
C6orf10 is not known, it has been described as a potential downstream effector of TNFα 
25.  
Our sample size was limited by the number of patients treated in the dermatology 
department. However, the limited sample size was counterbalanced by an exhaustive 
follow-up of patients and analysis of their data. Otherwise, we did not have enough 
statistical power to analyze each drug independently. We lost patients during the study 
at 6 and 12 months, but it is not clear how the problem that represents missing data may 
be addressed 43. Our data showed patients non-responders at 3 months that were 
responders at 6 months and  vice versa. For this reason, the main methodological 
approach used to analyze long-term efficacy data was “as-treated analysis”. The 
problem with using ITT-LOCF for analyzing long-term efficacy results is that this 
analysis method assumes that efficacy will remain constant (consistent with the last 
known value) 17. So, the results showed at 6 and 12 months of treatment should be 
considered as preliminary results due to missing data. 
The SNPs in FCGR2A, HTR2A, IL12B and CDKAL1 were replicated with ITT-LOCF 
analysis. In addition, SNPs in IL12B (rs2546890) and MAK3K1 (rs96844) were 
significant at 6 and 1 year of treatment. So these SNP remain being long-term 
biomarkers. Moreover, ITT-LOCF analysis showed 2 new SNPs in MAFB (rs6028945) 
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and QK1 (rs10945919) (Table S5; PASI75 at 6 months) and another one (rs191190) in 
TNFRSF1A (Table S6; PASI75 at 1 year) associated with response to anti-TNFs. The 
SNP in TNFRSF1A has been previously associated with psoriasis 14, 44, but not with 
response to the treatment. Furthermore, the SNPs in MAFB and QKI have been shown 
as possible predictors of response to anti-TNFs in patients with rheumatoid arthritis 45. 
 
In conclusion, ours is the first study to show an association between several SNPs—
rs2916205 (PGLYR4), rs9304742 (ZNF816A), rs11126740 (CTNNA2), rs2546890 
(IL12B), rs96844 (MAP3K1), and rs12191877 (HLA-C)—and response to anti-TNFs in 
psoriatic patients (PASI75 at 3 months of treatment). All of the SNPs have regulatory 
functions and are involved in immune responses or differentiation of keratinocytes in 
the skin. Therefore, they affect the development of psoriasis and the response to anti-
TNF drugs during the initial stages of treatment. The only SNPs replicated at 6 months 
were rs2546890 (IL12B) and rs96844 (MAP3K1). We also obtained significant results 
for rs2546890 (IL12B) at 1 year of treatment (PASI75). Finally, rs1801274 (FCGR2A), 
rs6311 (HTR2A), and rs6908425 (CDKAL1) were associated with response to anti-TNFs 
at 6 months and could be biomarkers of longer-term response. The results at 6 and 12 
months of treatment should be considered carefully due to missing data. 
Few studies have evaluated the effect of polymorphisms on the response to anti-TNF 
drugs 4-12. Consequently, our findings add to current knowledge on the 
pharmacogenomics of moderate-to-severe plaque psoriasis. However, large studies 
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Table 1. Phenotypic characteristics of psoriatic patients. 
 Naïve patients (N=144) 
Age at onset of psoriasis (years) 28.51 ± 14.04 
Men (%) 84 (58.33) 
Women (%) 60 (41.67) 
Weight (kg) 75.91 ± 13.74 
Psoriasis type I (%)1 120 (83.33) 
Psoriasis type II (%)2 24 (16.67) 
Patients with PsA (%) 35 (24.31) 
Presence of other comorbidities N (%):  
a. Dyslipidemia 53 (36.80) 
b. Hypertension 23 (16.00) 
c. Diabetes 15 (10.42) 
d. Obesity (BMI ≥ 30.0) 44 (30.56) 
Prior therapies N (%):  
a. Methotrexate 56 (38.89) 
b. Cyclosporine 81 (56.25) 
c. Acitretin 49 (34.03) 
d. Phototherapy 76 (52.78) 
e. Efalizumab 31 (21.53) 
Number of prior therapies before anti-TNF treatment 1 (1-4)* 
Wash-out periods (days) 28.18 ± 7.17 
Age at first anti-TNF agent (years) 43.61 ± 15.02 
Etanercept (%) 74 (51.39) 
Adalimumab (%) 42 (29.17) 
Infliximab (%) 28 (19.44) 
Baseline PASI 22.56 ± 10.97 
Clinical response at 3 months of treatment
PASI at 3 months 3.93 ± 4.68 
PASI 75 (%) 106 (73.61) 
PASI 90 (%) 66 (45.83) 
% improvement in PASI 81.83 ± 19.97 
Clinical response at 6 months of treatment
Missing data at 6 months# 11 
Patients with effectiveness data 133 
PASI at 6 months 3.57 ± 6.47 
PASI 75 (%) 102 (76.69) 
PASI 90 (%) 71 (49.31) 
% improvement in PASI 84.76 ± 21.30 
Clinical response at 1 year of treatment
Missing data at 1 year# 31 
Patients with effectiveness data 113 
PASI at 1 year 2.92 ± 4.65 
PASI 75 (%) 92 (81.42) 
PASI 90 (%) 69 (61.06) 
% improvement in PASI 86.77 ± 18.85 
 
Data are shown as mean ± SD, number (%) or *median (range); PsA: psoriatic arthritis; BMI: 
Body Mass Index; PASI: Psoriasis Area and Severity Index; #: data missing for the evaluation 
of the clinical response owing to lack of follow-up, side effects, remission, intermittent therapy, 




Table 2. Summary of the results of univariate and multivariate logistic regression analyses for PASI75 at 3 months of treatment (N=144). SNPs 
with p≤0.05 in the univariate analysis were included in the multivariate analysis (Table S1). Only polymorphisms that were significant for anti-
TNF drugs in the multivariate analysis are shown.  








OR* (95% CI) p-value OR* (95% CI) p-value 
rs2916205 PGLYRP4-24 D AG/GG (20.8/39.5) 2.49 (1.12-5.55) 0.027 3.62 (1.00-13.07) 0.050 
rs9304742 ZNF816A R CC (9.4/23.7) 2.98 (1.11-8.03) 0.034 7.66 (1.37-42.70) 0.020 
rs11126740 CTNNA2 R AA (4.8/23.7) 6.14 (1.91-19.78) 0.0018 20.56 (2.75-153.69) 0.003 
rs2546890 IL12B A AG/GG (72.4/84.2) 1.91 (1.098-3.38) 0.024 3.22 (1.23-8.40) 0.017 
rs96844 MAP3K1 A CT/CC (55.7/31.6) 0.41 (0.21-0.83) 0.0081 0.17 (0.05-0.56) 0.004 
rs12191877 HLA-C A CT/TT (70.8/52.6) 0.46 (0.24-0.87) 0.013 0.30 (0.11-0.88) 0.027 
 
Abbreviations: PGLYRP4-24: peptidoglycan recognition protein 4, 24; ZNF816A: zinc finger protein 816; CTNNA2: catenin (cadherin-associated protein), 
alpha 2; IL12B: interleukin 12B; MAP3K1: mitogen-activated protein 3 kinase 1; HLA-C: major histocompatibility complex, class I, C; SNP: single-









Table 3. Summary of results of univariate and multivariate logistic regression analyses for PASI75 at 6 months of treatment (N=133). SNPs with 
p≤0.05 in the univariate analysis were included in the multivariate analysis (Table S2). Only polymorphisms that were significant in the 
multivariate analysis for anti-TNF drugs are shown.  




UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS 
OR* (95% CI) p-value OR* (95% CI) p-value 
rs1801274 FCGR2A D CT/CC (73.5/93.5) 5.22 (1.17-23.37) 0.009 13.32 (1.67-106.50) 0.015 
rs6311 HTR2A D CT/TT (65.7/89.7) 4.53 (1.28-16.06) 0.007 5.60 (1.10-28.63) 0.038 
rs2546890 IL12B A AG/GG (71.6/90.3) 2.16 (1.14-4.08) 0.014 4.14 (1.23-13.81) 0.022 
rs96844 MAP3K1 D CT/CC (54.9/22.6) 0.24 (0.09-0.61) 0.001 0.24 (0.06-0.97) 0.045 
rs6908425 CDKAL1 A CT/TT (30.4/12.9) 0.35 (0.12-1.00) 0.026 0.14 (0.03-0.66) 0.013 
 
Abbreviations: FCGR2A: Fc fragment of IgG, low affinity IIa, receptor (CD32); HTR2A: 5-hydroxytryptamine (serotonin) receptor 2A; IL12B: interleukin 
12B; MAP3K1: mitogen-activated protein 3 kinase 1; CDKAL1: CDK5 regulatory subunit associated protein 1-like 1; SNP: single-nucleotide polymorphism; 










Table 4. Summary of results of univariate and multivariate logistic regression analyses for PASI75 at 1 year of treatment (N=113). SNPs with 
p≤0.05 in the univariate analysis were included in the multivariate analysis (Table S3). Only polymorphisms that were significant in the 
multivariate analysis for anti-TNF drugs are shown.  




UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS 
OR* (95% CI) p-value OR* (95% CI) p-value 
rs2546890 IL12B A AG/GG (73.9/90.5) 2.99 (1.34-6.66) 0.005 2.79 (1.02-7.64) 0.046 
 
Abbreviations: IL12B: interleukin 12B; SNP: single-nucleotide polymorphism; OR: odds ratio; CI: confidence interval; A: additive; *: odds ratio of non-
response. 
 
 
 
 
 
 
 
 
 
 
